News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
743,989 Results
Type
Article (43893)
Company Profile (317)
Press Release (699764)
Multimedia
Podcasts (118)
Webinars (20)
Section
Business (211017)
Career Advice (2111)
Deals (36764)
Drug Delivery (129)
Drug Development (83441)
Employer Resources (176)
FDA (16853)
Job Trends (15508)
News (357450)
Policy (34142)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2619)
Accelerated approval (38)
Adcomms (26)
Allergies (159)
Alliances (51584)
ALS (182)
Alzheimer's disease (1708)
Antibody-drug conjugate (ADC) (346)
Approvals (17129)
Artificial intelligence (571)
Autoimmune disease (179)
Automation (45)
Bankruptcy (372)
Best Places to Work (11769)
BIOSECURE Act (21)
Biosimilars (200)
Biotechnology (189)
Bladder cancer (167)
Brain cancer (64)
Breast cancer (664)
Cancer (5089)
Cardiovascular disease (438)
Career advice (1793)
Career pathing (39)
CAR-T (292)
CDC (53)
Celiac Disease (2)
Cell therapy (779)
Cervical cancer (39)
Clinical research (71416)
Collaboration (1840)
Company closure (4)
Compensation (1218)
Complete response letters (69)
COVID-19 (2791)
CRISPR (104)
C-suite (928)
Cystic fibrosis (150)
Data (6575)
Decentralized trials (2)
Denatured (36)
Depression (144)
Diabetes (519)
Diagnostics (6842)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (275)
Drug pricing (206)
Drug shortages (31)
Duchenne muscular dystrophy (243)
Earnings (92330)
Editorial (61)
Employer branding (21)
Employer resources (155)
Events (120807)
Executive appointments (1024)
FDA (20116)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (25)
Funding (1547)
Gene editing (214)
Generative AI (46)
Gene therapy (645)
GLP-1 (1031)
Government (4823)
Grass and pollen (7)
Guidances (386)
Healthcare (19082)
HIV (68)
Huntington's disease (51)
IgA nephropathy (87)
Immunology and inflammation (270)
Immuno-oncology (67)
Indications (135)
Infectious disease (3077)
Inflammatory bowel disease (204)
Inflation Reduction Act (14)
Influenza (123)
Intellectual property (263)
Interviews (327)
IPO (16926)
IRA (57)
Job creations (4070)
Job search strategy (1500)
JPM (65)
Kidney cancer (18)
Labor market (89)
Layoffs (578)
Leadership (35)
Legal (8425)
Liver cancer (95)
Longevity (21)
Lung cancer (679)
Lymphoma (389)
Machine learning (47)
Management (60)
Manufacturing (866)
MASH (175)
Medical device (13892)
Medtech (13956)
Mergers & acquisitions (20947)
Metabolic disorders (1349)
mRNA (172)
Multiple sclerosis (170)
NASH (17)
Neurodegenerative disease (345)
Neuropsychiatric disorders (94)
Neuroscience (3035)
Neurotech (1)
NextGen: Class of 2026 (6647)
Non-profit (4567)
Now hiring (69)
Obesity (641)
Opinion (295)
Ovarian cancer (173)
Pain (231)
Pancreatic cancer (243)
Parkinson's disease (298)
Partnered (34)
Patents (528)
Patient recruitment (536)
Peanut (63)
People (61066)
Pharmaceutical (88)
Pharmacy benefit managers (32)
Phase 1 (22164)
Phase 2 (31405)
Phase 3 (23532)
Pipeline (6091)
Policy (312)
Postmarket research (2655)
Preclinical (9411)
Press Release (68)
Prostate cancer (258)
Psychedelics (51)
Radiopharmaceuticals (299)
Rare diseases (940)
Real estate (6308)
Recruiting (72)
Regulatory (25594)
Reports (53)
Research institute (2449)
Resumes & cover letters (362)
Rett syndrome (30)
RNA editing (17)
RSV (81)
Schizophrenia (160)
Series A (260)
Series B (196)
Service/supplier (11)
Sickle cell disease (104)
Special edition (25)
Spinal muscular atrophy (161)
Sponsored (43)
Startups (3769)
State (2)
Stomach cancer (19)
Supply chain (111)
Tariffs (96)
The Weekly (80)
Vaccines (1051)
Venture capital (93)
Weight loss (416)
Women's health (101)
Worklife (19)
Date
Last 7 days (724)
Last 30 days (2864)
Last 365 days (30323)
2026 (5648)
2025 (30684)
2024 (35766)
2023 (40629)
2022 (51798)
2021 (56330)
2020 (54791)
2019 (47397)
2018 (35770)
2017 (33136)
2016 (32662)
2015 (38615)
2014 (32517)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (800)
Alabama (86)
Alaska (7)
Arizona (324)
Arkansas (15)
Asia (42235)
Australia (6765)
California (11825)
Canada (3412)
China (1176)
Colorado (497)
Connecticut (503)
Delaware (349)
Europe (90684)
Florida (1775)
Georgia (374)
Hawaii (3)
Idaho (61)
Illinois (922)
India (76)
Indiana (548)
Iowa (22)
Japan (464)
Kansas (127)
Kentucky (43)
Louisiana (34)
Maine (73)
Maryland (1438)
Massachusetts (8506)
Michigan (340)
Minnesota (648)
Mississippi (6)
Missouri (131)
Montana (33)
Nebraska (29)
Nevada (130)
New Hampshire (80)
New Jersey (3150)
New Mexico (29)
New York (3111)
North Carolina (1527)
North Dakota (8)
Northern California (5805)
Ohio (350)
Oklahoma (22)
Oregon (46)
Pennsylvania (2392)
Puerto Rico (24)
Rhode Island (49)
South America (1175)
South Carolina (70)
South Dakota (1)
Southern California (4624)
Tennessee (188)
Texas (1829)
United States (41988)
Utah (355)
Vermont (1)
Virginia (290)
Washington D.C. (80)
Washington State (955)
West Virginia (4)
Wisconsin (120)
Wyoming (2)
743,989 Results for "ultragenyx pharmaceutical inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Gene therapy
Ultragenyx’s Gene Therapy Shows Long-Term Efficacy in Two Sanfilippo Studies
The FDA in July last year declined to approve UX111 for Sanfilippo syndrome, a rare neurodegenerative disorder, citing manufacturing issues. Ultragenyx Pharmaceutical resubmitted its application ten days ago, expecting a six month review time.
February 9, 2026
·
2 min read
·
Tristan Manalac
Phase III
Ultragenyx Loses $1B in Market Value as Bone Drug Fails To Reduce Fractures
With a pair of Phase III trial flops, Ultragenyx will explore cost reductions as analysts turn attention to an upcoming Angelman syndrome readout.
January 2, 2026
·
2 min read
·
Annalee Armstrong
Press Releases
Ultragenyx to Participate at Investor Conferences in March 2026
February 24, 2026
·
1 min read
Press Releases
Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
February 12, 2026
·
12 min read
Press Releases
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 20, 2026
February 22, 2026
·
1 min read
Press Releases
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update
February 6, 2026
·
1 min read
Press Releases
Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 8, 2026
·
1 min read
Rare diseases
Ultragenyx Takes Second Hit as FDA Rejects Gene Therapy for Sanfilippo Syndrome
The FDA cited manufacturing issues but did not flag problems with Ultragenyx’s data package for UX111, with the biotech noting that the regulator found its neurodevelopmental findings for the gene therapy to be “robust.”
July 14, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
January 12, 2026
·
7 min read
Press Releases
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 23, 2026
January 26, 2026
·
1 min read
1 of 74,399
Next
